Primo-indication
Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
Intervention Type
Pharmaceutical
Solid/Hematological
Solid
Cancer Type
Prostate
Therapy Types
Hormone Therapy
Regulatory
FDA
N/A
Regulatory Pathway: n/a
EMA
14.01.2019
Regulatory Pathway: standard approval
Availability in other countries
N/A
Focus Area
Cancer
ASMR
III
Medical Need
Unmet
SMR
IMPORTANT
Orphan Status
No